Evidence profile
Melanotan II
Melanotan II study rows link each listed finding to its source, model or population, and endpoint.
Cited headline finding
The case report described melanoma temporally associated with reported exposure; the case report does not establish causality. ↗
Single-patient case reportHjuler & Lorentzen, Dermatology 2014Observational
Mechanism scope
How cited research characterizes Melanotan II
The cited Phase 1 report describes melanotropic activity in fewer than three healthy male volunteers.
Sources: Dorr et al., Life Sciences 1996 ↗
Open question
What the cited Melanotan II sources do not resolve
The cited Melanotan II case reports describe temporal associations and do not establish causality.
Sources: Hjuler & Lorentzen, Dermatology 2014 ↗ · Schulze et al., European Journal of Dermatology 2014 ↗ · Mallory et al., Sexual Medicine 2021 ↗
| Finding | Year | n | Model or population | Endpoint | Source | Evidence tier |
|---|---|---|---|---|---|---|
| The case report described priapism temporally associated with reported exposure; the case report does not establish causality. | 2021 | Single-patient | Single-patient case report | Reported clinical presentation | Mallory et al., Sexual Medicine 2021 ↗ | Observational |
| The case report described melanoma temporally associated with reported exposure; the case report does not establish causality. | 2014 | Single-patient | Single-patient case report | Reported clinical presentation | Hjuler & Lorentzen, Dermatology 2014 ↗ | Observational |
| The case report described eruptive and darkened naevi temporally associated with reported exposure; the case report does not establish causality. | 2014 | Single-patient | Single-patient case report | Reported clinical presentation | Schulze et al., European Journal of Dermatology 2014 ↗ | Observational |
| The Phase 1 report described melanotropic activity and observed effects in fewer than three volunteers. | 1996 | Fewer than three | Fewer than three healthy male volunteers | Melanotropic activity and observed effects | Dorr et al., Life Sciences 1996 ↗ | Phase 1–2 |
Regulatory status
Melanotan II appears in Health Canada's peptide-drug advisory. ↗
Reviewer: Ember Peptides source-verification editorial review · Review date: 2026-09-13